Transgenic Sertoli Cells as a Vehicle for Gene Therapy
Gene therapy involves the manipulation of genetic material to replace defective or deficient proteins to restore function in disease states. These genes are introduced into cells by mechanical, chemical, and biological approaches. To date, cell-based gene therapy has been hampered by the lack of an...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2004-01-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.3727/000000004772664833 |
id |
doaj-9a4e0cff3d2641649b6be3c2d45b0bd7 |
---|---|
record_format |
Article |
spelling |
doaj-9a4e0cff3d2641649b6be3c2d45b0bd72020-11-25T03:27:18ZengSAGE PublishingCell Transplantation0963-68971555-38922004-01-011310.3727/000000004772664833Transgenic Sertoli Cells as a Vehicle for Gene TherapyJannette M. Dufour0Paul Gores1Richelle Hemendinger2Dwaine F. Emerich3Craig R. Halberstadt Ph.D.4Surgical-Medical Research Institute, Department of Surgery, University of Alberta, Edmonton T6G 2N8, CanadaDepartment of General Surgery and The Transplant Center, Carolinas Medical Center, Charlotte, NC 28232Department of General Surgery and The Transplant Center, Carolinas Medical Center, Charlotte, NC 28232Sertoli Technologies, Inc., Cranston, RI 02905Department of General Surgery and The Transplant Center, Carolinas Medical Center, Charlotte, NC 28232Gene therapy involves the manipulation of genetic material to replace defective or deficient proteins to restore function in disease states. These genes are introduced into cells by mechanical, chemical, and biological approaches. To date, cell-based gene therapy has been hampered by the lack of an abundant, safe, and immunologically acceptable source of tissue. As an alternative, transgenic animals designed to produce therapeutic proteins could overcome some of the issues facing gene therapy but the problem of immune rejection of the tissue remains. This article reports on recently published work indicating the potential to use transgenic Sertoli cells surviving in an allogeneic host by virtue of their ability to create a locally immunoprivileged environment, thereby providing for the continued delivery of a therapeutic protein to the systemic circulation.https://doi.org/10.3727/000000004772664833 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jannette M. Dufour Paul Gores Richelle Hemendinger Dwaine F. Emerich Craig R. Halberstadt Ph.D. |
spellingShingle |
Jannette M. Dufour Paul Gores Richelle Hemendinger Dwaine F. Emerich Craig R. Halberstadt Ph.D. Transgenic Sertoli Cells as a Vehicle for Gene Therapy Cell Transplantation |
author_facet |
Jannette M. Dufour Paul Gores Richelle Hemendinger Dwaine F. Emerich Craig R. Halberstadt Ph.D. |
author_sort |
Jannette M. Dufour |
title |
Transgenic Sertoli Cells as a Vehicle for Gene Therapy |
title_short |
Transgenic Sertoli Cells as a Vehicle for Gene Therapy |
title_full |
Transgenic Sertoli Cells as a Vehicle for Gene Therapy |
title_fullStr |
Transgenic Sertoli Cells as a Vehicle for Gene Therapy |
title_full_unstemmed |
Transgenic Sertoli Cells as a Vehicle for Gene Therapy |
title_sort |
transgenic sertoli cells as a vehicle for gene therapy |
publisher |
SAGE Publishing |
series |
Cell Transplantation |
issn |
0963-6897 1555-3892 |
publishDate |
2004-01-01 |
description |
Gene therapy involves the manipulation of genetic material to replace defective or deficient proteins to restore function in disease states. These genes are introduced into cells by mechanical, chemical, and biological approaches. To date, cell-based gene therapy has been hampered by the lack of an abundant, safe, and immunologically acceptable source of tissue. As an alternative, transgenic animals designed to produce therapeutic proteins could overcome some of the issues facing gene therapy but the problem of immune rejection of the tissue remains. This article reports on recently published work indicating the potential to use transgenic Sertoli cells surviving in an allogeneic host by virtue of their ability to create a locally immunoprivileged environment, thereby providing for the continued delivery of a therapeutic protein to the systemic circulation. |
url |
https://doi.org/10.3727/000000004772664833 |
work_keys_str_mv |
AT jannettemdufour transgenicsertolicellsasavehicleforgenetherapy AT paulgores transgenicsertolicellsasavehicleforgenetherapy AT richellehemendinger transgenicsertolicellsasavehicleforgenetherapy AT dwainefemerich transgenicsertolicellsasavehicleforgenetherapy AT craigrhalberstadtphd transgenicsertolicellsasavehicleforgenetherapy |
_version_ |
1724588418628845568 |